CN109073637A - 用于预测蛋白质或蛋白质片段用于免疫治疗的有用性的方法 - Google Patents

用于预测蛋白质或蛋白质片段用于免疫治疗的有用性的方法 Download PDF

Info

Publication number
CN109073637A
CN109073637A CN201780026579.0A CN201780026579A CN109073637A CN 109073637 A CN109073637 A CN 109073637A CN 201780026579 A CN201780026579 A CN 201780026579A CN 109073637 A CN109073637 A CN 109073637A
Authority
CN
China
Prior art keywords
protein
cell
fragment
disease
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780026579.0A
Other languages
English (en)
Chinese (zh)
Inventor
马蒂亚斯·沃尔梅尔
乌尔·沙欣
芭芭拉·施勒尔斯
马丁·勒韦尔
塞巴斯蒂安·伯格尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Debiotech SA
TRON Translationale Onkologie an der Universitaetsmedizin der Johannes Gutenberg Universitaet Mainz gGmbH
Original Assignee
Biotechnology Rna Pharmaceutical Co Ltd
TRON Translationale Onkologie an der Universitaetsmedizin der Johannes Gutenberg Universitaet Mainz gGmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotechnology Rna Pharmaceutical Co Ltd, TRON Translationale Onkologie an der Universitaetsmedizin der Johannes Gutenberg Universitaet Mainz gGmbH filed Critical Biotechnology Rna Pharmaceutical Co Ltd
Publication of CN109073637A publication Critical patent/CN109073637A/zh
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in epitope analysis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5035—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on sub-cellular localization
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4712—Muscle proteins, e.g. myosin, actin, protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN201780026579.0A 2016-05-13 2017-05-10 用于预测蛋白质或蛋白质片段用于免疫治疗的有用性的方法 Pending CN109073637A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2016/060897 WO2017194170A1 (en) 2016-05-13 2016-05-13 Methods for predicting the usefulness of proteins or protein fragments for immunotherapy
EPPCT/EP2016/060897 2016-05-13
PCT/EP2017/061196 WO2017194610A1 (en) 2016-05-13 2017-05-10 Methods for predicting the usefulness of proteins or protein fragments for immunotherapy

Publications (1)

Publication Number Publication Date
CN109073637A true CN109073637A (zh) 2018-12-21

Family

ID=55971007

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780026579.0A Pending CN109073637A (zh) 2016-05-13 2017-05-10 用于预测蛋白质或蛋白质片段用于免疫治疗的有用性的方法

Country Status (27)

Country Link
US (2) US12153041B2 (https=)
EP (3) EP4411376A3 (https=)
JP (5) JP7529381B2 (https=)
KR (3) KR20220020993A (https=)
CN (1) CN109073637A (https=)
AU (2) AU2017264546B2 (https=)
BR (1) BR112018073221A2 (https=)
CA (1) CA3022654A1 (https=)
CY (1) CY1123520T1 (https=)
DK (2) DK3792628T3 (https=)
ES (2) ES2826480T3 (https=)
FI (1) FI3792628T3 (https=)
HR (2) HRP20240704T1 (https=)
HU (2) HUE067497T2 (https=)
IL (2) IL300841A (https=)
LT (2) LT3455625T (https=)
MA (1) MA43794B1 (https=)
MD (1) MD3455625T2 (https=)
MX (2) MX393653B (https=)
PL (2) PL3455625T3 (https=)
PT (2) PT3792628T (https=)
RS (2) RS65568B1 (https=)
SG (1) SG11201808495SA (https=)
SI (2) SI3792628T1 (https=)
SM (2) SMT202400232T1 (https=)
WO (2) WO2017194170A1 (https=)
ZA (1) ZA201805809B (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110534156A (zh) * 2019-09-02 2019-12-03 深圳市新合生物医疗科技有限公司 一种提取免疫治疗新抗原的方法及系统
CN111487399A (zh) * 2020-03-26 2020-08-04 湖南师范大学 一种蛋白分子标记在鱼类生殖细胞发育研究中的应用
CN111621564A (zh) * 2019-02-28 2020-09-04 武汉大学 一种鉴定有效肿瘤新抗原的方法
CN113711239A (zh) * 2019-03-06 2021-11-26 磨石生物公司 利用ii类mhc模型鉴别新抗原

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL260030B2 (en) 2016-01-08 2025-12-01 Nykode Therapeutics ASA Therapeutic anticancer neoepitope vaccine
WO2017194170A1 (en) 2016-05-13 2017-11-16 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of proteins or protein fragments for immunotherapy
EP3933408A1 (en) 2017-05-30 2022-01-05 Nant Holdings IP LLC Circulating tumor cell enrichment using neoepitopes
JP6857930B2 (ja) * 2018-02-15 2021-04-14 国立大学法人旭川医科大学 がん抗原ペプチド
CA3106564A1 (en) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Cancer vaccines for breast cancer
US20220349010A1 (en) 2018-07-26 2022-11-03 Frame Pharmaceuticals B.V. Method of preparing subject-specific immunogenic compositions based on a neo open-reading-frame peptide database
CN109021062B (zh) * 2018-08-06 2021-08-20 倍而达药业（苏州）有限公司 一种肿瘤新抗原的筛选方法
WO2023025404A1 (en) 2021-08-24 2023-03-02 BioNTech SE In vitro transcription technologies
WO2024083345A1 (en) 2022-10-21 2024-04-25 BioNTech SE Methods and uses associated with liquid compositions
WO2025202937A1 (en) 2024-03-26 2025-10-02 BioNTech SE Cancer vaccines

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1265038A (zh) * 1997-07-16 2000-08-30 法国国家卫生及研究医学协会 被称作胞外体的细胞囊泡,其制备方法及在免疫刺激中的用途
WO2006105255A2 (en) * 2005-03-29 2006-10-05 The Board Of Trustees Of The University Of Illinois Cancer vaccines and therapeutic methods
US20090280511A1 (en) * 2008-05-12 2009-11-12 Medical And Biological Laboratories Co., Ltd. Methods for selecting candidate peptides presented on the surface of cancer cells following their binding to MHC class I molecules
EP2172212A2 (en) * 2008-10-01 2010-04-07 Immatics Biotechnologies GmbH Novel immunotherapy against several tumors including neuronal and brain tumors
CN102119170A (zh) * 2008-06-10 2011-07-06 肿瘤疗法科学股份有限公司 Mybl2表位肽及包含它的疫苗
WO2012164004A1 (en) * 2011-06-01 2012-12-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Novel antigen peptide and uses thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1276896T3 (da) * 2000-04-28 2010-10-18 Mannkind Corp Epitop-synkronisering i antigen-præsenterende celler
CA2415902A1 (en) 2000-07-10 2002-01-17 Xencor Protein design automation for designing protein libraries with altered immunogenicity
JP4900884B2 (ja) * 2000-07-31 2012-03-21 株式会社グリーンペプタイド 腫瘍抗原
DE10225139A1 (de) 2002-05-29 2004-02-26 Immatics Biotechnologies Gmbh Verfahren zur Identifizierung von immunreaktiven Peptiden
TW200413539A (en) * 2002-09-30 2004-08-01 Oncotherapy Science Inc Genes and polypeptides relating to prostate cancers
CA2755983A1 (en) 2009-03-23 2010-09-30 The Walter And Eliza Hall Institute Of Medical Research Compounds and methods for modulating an immune response
AU2010310468A1 (en) * 2009-10-23 2012-05-24 Mannkind Corporation Cancer immunotherapy and method of treatment
PL3892295T3 (pl) 2011-05-24 2023-07-24 BioNTech SE Zindywidualizowane szczepionki przeciwnowotworowe
WO2012159643A1 (en) 2011-05-24 2012-11-29 Biontech Ag Individualized vaccines for cancer
GB201319446D0 (en) 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
ES2970865T3 (es) 2015-12-16 2024-05-31 Gritstone Bio Inc Identificación, fabricación y uso de neoantígenos
WO2017194170A1 (en) 2016-05-13 2017-11-16 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of proteins or protein fragments for immunotherapy
CA3060569A1 (en) 2017-04-19 2018-10-25 Gritstone Oncology, Inc. Neoantigen identification, manufacture, and use
AU2018279627B2 (en) 2017-06-09 2023-08-10 Seattle Project Corp. Neoantigen identification, manufacture, and use
US20200363414A1 (en) 2017-09-05 2020-11-19 Gritstone Oncology, Inc. Neoantigen Identification for T-Cell Therapy
EP4576103A3 (en) 2017-10-10 2025-08-27 Gritstone bio, Inc. Neoantigen identification using hotspots
CN111630602A (zh) 2017-11-22 2020-09-04 磨石肿瘤生物技术公司 减少新抗原的接合表位呈递
EP3759131A4 (en) 2018-02-27 2021-12-01 Gritstone bio, Inc. NEOANTIGEN IDENTIFICATION WITH PAN ALLELE MODELS

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1265038A (zh) * 1997-07-16 2000-08-30 法国国家卫生及研究医学协会 被称作胞外体的细胞囊泡,其制备方法及在免疫刺激中的用途
CN1250285C (zh) * 1997-07-16 2006-04-12 法国国家卫生及研究医学协会 被称作胞外体的细胞囊泡,其制备方法及在免疫刺激中的用途
WO2006105255A2 (en) * 2005-03-29 2006-10-05 The Board Of Trustees Of The University Of Illinois Cancer vaccines and therapeutic methods
US20090280511A1 (en) * 2008-05-12 2009-11-12 Medical And Biological Laboratories Co., Ltd. Methods for selecting candidate peptides presented on the surface of cancer cells following their binding to MHC class I molecules
CN102119170A (zh) * 2008-06-10 2011-07-06 肿瘤疗法科学股份有限公司 Mybl2表位肽及包含它的疫苗
EP2172212A2 (en) * 2008-10-01 2010-04-07 Immatics Biotechnologies GmbH Novel immunotherapy against several tumors including neuronal and brain tumors
WO2012164004A1 (en) * 2011-06-01 2012-12-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Novel antigen peptide and uses thereof

Non-Patent Citations (20)

* Cited by examiner, † Cited by third party
Title
BO JIN 等: ""Immunomodulatory effects of dsRNA and its potential as vaccine adjuvant"", 《J BIOMED BIOTECHNOL》 *
BRIAN M ANDERSEN 等: ""Increasing the efficacy of tumor cell vaccines by enhancing cross priming"", 《CANCER LETT》 *
D RIMOLDI 等: ""Subcellular localization of the melanoma-associated protein Melan-AMART-1 influences the processing of its HLA-A2-restricted epitope"", 《J BIOL CHEM》 *
GIORGIO PARMIANI 等: ""Unique Human Tumor Antigens: Immunobiology and Use in Clinical Trials"", 《J IMMUNOL》 *
GORDON D BROWN: ""Immunology: Actin" dangerously"", 《NATURE》 *
INGRID S ZEELENBERG 等: ""Antigen localization controls T cell-mediated tumor immunity"", 《J IMMUNOL》 *
J WOLFERS 等: ""Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming"", 《NAT MED》 *
LENE ALSØE 等: ""Identification of prostate cancer antigens by automated high-throughput filter immunoscreening"", 《J IMMUNOL METHODS》 *
MARIOLINA SALIO 等: ""Viral immunity: cross-priming with the help of TLR3"", 《CURR BIOL》 *
MICHAEL KOSLOWSKI 等: ""A placenta-specific gene ectopically activated in many human cancers is essentially involved in malignant cell processes"", 《CANCER RES》 *
NIR HACOHEN 等: ""Getting personal with neoantigen-based therapeutic cancer vaccines"", 《CANCER IMMUNOL RES》 *
NORIAKI NAKAI 等: ""Immunoregulatory T cells in the peripheral blood of melanoma patients treated with melanoma antigen-pulsed mature monocyte-derived dendritic cell vaccination"", 《JOURNAL OF DERMATOLOGICAL SCIENCE》 *
ÖZLEM TÜRECI 等: ""Targeting the Heterogeneity of Cancer with Individualized Neoepitope Vaccines"", 《CLIN CANCER RES》 *
PRAMOD K SRIVASTAVA: ""Neoepitopes of Cancers: Looking Back, Looking Ahead"", 《CANCER IMMUNOL RES》 *
UTA BEHRENDS 等: ""Novel tumor antigens identified by auto...ildhood medulloblastoma cDNA libraries"", 《INT J CANCER》 *
V BONCHEVA 等: ""New targets for the immunotherapy of colon cancer-does reactive disease hold the answer?"", 《CANCER GENE THER》 *
YUNWEI WANG 等: ""Perspectives of SEREX-defined antigens in diagnosis and immunotherapy for gastric cancer"", 《CANCER BIOL THER》 *
夏和先 等: "《病原生物学与免疫学基础》", 30 April 2015, 东南大学出版社 *
无: ""Nature：肿瘤特异性抗原表位检测，推动个体化肿瘤免疫治疗"", 《现代生物医学进展》 *
无: ""癌症治疗性疫苗IMA-901"", 《药学进展》 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111621564A (zh) * 2019-02-28 2020-09-04 武汉大学 一种鉴定有效肿瘤新抗原的方法
CN111621564B (zh) * 2019-02-28 2022-03-25 武汉大学 一种鉴定有效肿瘤新抗原的方法
CN113711239A (zh) * 2019-03-06 2021-11-26 磨石生物公司 利用ii类mhc模型鉴别新抗原
CN110534156A (zh) * 2019-09-02 2019-12-03 深圳市新合生物医疗科技有限公司 一种提取免疫治疗新抗原的方法及系统
CN110534156B (zh) * 2019-09-02 2022-06-17 深圳市新合生物医疗科技有限公司 一种提取免疫治疗新抗原的方法及系统
CN111487399A (zh) * 2020-03-26 2020-08-04 湖南师范大学 一种蛋白分子标记在鱼类生殖细胞发育研究中的应用

Also Published As

Publication number Publication date
ES2826480T3 (es) 2021-05-18
PT3455625T (pt) 2020-10-22
HUE052240T2 (hu) 2021-04-28
IL262680B1 (en) 2023-04-01
RS61071B1 (sr) 2020-12-31
IL300841A (en) 2023-04-01
JP2022081492A (ja) 2022-05-31
AU2017264546B2 (en) 2022-04-28
US20250244311A1 (en) 2025-07-31
JP2024096712A (ja) 2024-07-17
EP3455625B1 (en) 2020-09-02
WO2017194610A1 (en) 2017-11-16
PL3792628T3 (pl) 2024-07-15
AU2022209286A1 (en) 2022-08-25
ZA201805809B (en) 2020-12-23
HUE067497T2 (hu) 2024-10-28
KR20240146087A (ko) 2024-10-07
KR102358620B1 (ko) 2022-02-07
EP3792628B1 (en) 2024-04-24
EP4411376A3 (en) 2025-03-19
FI3792628T3 (fi) 2024-06-07
KR20190008218A (ko) 2019-01-23
HRP20201671T1 (hr) 2021-03-05
RU2018137721A3 (https=) 2020-08-25
EP3792628A2 (en) 2021-03-17
US12153041B2 (en) 2024-11-26
DK3455625T3 (da) 2020-10-26
PL3455625T3 (pl) 2021-01-25
JP7529381B2 (ja) 2024-08-06
HRP20240704T1 (hr) 2024-09-27
LT3792628T (lt) 2024-06-25
EP3455625A1 (en) 2019-03-20
BR112018073221A2 (pt) 2019-02-19
SI3792628T1 (sl) 2024-08-30
MX2018013081A (es) 2019-01-24
DK3792628T3 (da) 2024-06-17
AU2017264546A1 (en) 2018-10-18
IL262680B2 (en) 2023-08-01
MX2022007902A (es) 2022-07-21
PT3792628T (pt) 2024-06-18
SMT202000622T1 (it) 2021-01-05
CA3022654A1 (en) 2017-11-16
IL262680A (en) 2018-12-31
US20190178871A1 (en) 2019-06-13
JP2024112805A (ja) 2024-08-21
SI3455625T1 (sl) 2021-01-29
JP2024160216A (ja) 2024-11-13
RS65568B1 (sr) 2024-06-28
MX393653B (es) 2025-03-24
SMT202400232T1 (it) 2024-07-09
SG11201808495SA (en) 2018-10-30
MD3455625T2 (ro) 2020-12-31
EP3792628A3 (en) 2021-05-19
CY1123520T1 (el) 2022-03-24
EP4411376A2 (en) 2024-08-07
ES2980781T3 (es) 2024-10-03
MA43794B1 (fr) 2020-12-31
KR20220020993A (ko) 2022-02-21
MA43794A (fr) 2019-03-20
LT3455625T (lt) 2021-01-11
RU2018137721A (ru) 2020-06-15
WO2017194170A1 (en) 2017-11-16
JP2019520554A (ja) 2019-07-18

Similar Documents

Publication Publication Date Title
US20250244311A1 (en) Methods for predicting the usefulness of proteins or protein fragments for immunotherapy
CN109310739A (zh) 新抗原及其使用方法
KR102560750B1 (ko) 면역요법을 위한 질환 특이적 아미노산 변형의 유용성을 예측하는 방법
KR20240095527A (ko) 예방접종에 유용한 t 세포 에피토프의 예측 방법
CN109477149A (zh) 选择新表位作为具有增强效力的用于治疗的疾病特异性靶标
JP2015520129A (ja) 多価乳がんワクチン
Kramer et al. Functionalisation of virus‐like particles enhances antitumour immune responses
CN109891238A (zh) 免疫治疗剂的剂量确定
He et al. Antitumor efficacy induced by a B16F10 tumor cell vaccine treated with mitoxantrone alone or in combination with reserpine and verapamil in mice
HK40114873A (en) Methods for predicting the usefulness of neoantigens for immunotherapy
RU2782336C2 (ru) Способы прогнозирования применимости белков или белковых фрагментов для иммунотерапии
HK40049190B (en) Methods for predicting the usefulness of neoantigens for immunotherapy
HK40049190A (en) Methods for predicting the usefulness of neoantigens for immunotherapy
NZ787614A (en) Methods for predicting the usefulness of proteins or protein fragments for immunotherapy
HK1262104A1 (en) Methods for predicting the usefulness of neoantigens for immunotherapy
HK1262104B (en) Methods for predicting the usefulness of neoantigens for immunotherapy
HK40002506A (en) Methods for predicting the usefulness of proteins or protein fragments for immunotherapy
HK40020601B (zh) 用於预测疾病特异性氨基酸修饰用於免疫治疗的可用性的方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40002506

Country of ref document: HK

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20220120

Address after: Mainz, Germany

Applicant after: DEBIOTECH S.A.

Applicant after: John Gutenberg University Mainz Medical University translational oncology company

Address before: Mainz, Germany

Applicant before: BIONTECH RNA PHARMACEUTICALS GmbH

Applicant before: John Gutenberg University Mainz Medical University translational oncology company